KA/EN
Register
Medicines reference
Search
Search
Product

Bravecto Plus

Favourites

Fluralaner + Moxidectin · MSD Animal Health, Intervet International B.V.

3 forms: spot-on. In force in Georgia: 3 of 3 (veterinary register).

Forms and doses3 of 3 in force in Georgia

The dose from the product's label, by species and weight. Check the label of the pack you use.

Choose species and weight; the matching row will be highlighted.
Form Species Weight Dose Frequency Georgia
112.5 mg/5.6 mg, Spot-on · Cat 1.2–2.8 kg Cat 1.2–2.8 kg 1 pipette
corresponding to a dose of 40-94 mg fluralaner/kg body weight and 2-4.7 mg moxidectin/kg body weight Within each weight band, the content of one whole pipette should be used. Where necessary, cats can be re-treated at 12-week intervals. In the absence of available data, treatment of kittens less than 9 weeks of age and cats less than 1.2 kg bodyweight is not recommended. use in such animals is not recommended
 · once; if needed every 12 weeks		 once; if needed every 12 weeks Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ბრავექტო™ პლუს 112.5მგ/5.6მგ გარეგანი გამოყენების ხსნარი პატარა ზომის კატებისთვის (1.2-2.8კგ)
№ 373-11
Verified on: 15 Oct 2026
112.5 mg/5.6 mg, Spot-on · Dog Any weight Dog Any weight No dose for this species
This product is labelled only for cats; no canine dose is established.
 - Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ბრავექტო™ პლუს 112.5მგ/5.6მგ გარეგანი გამოყენების ხსნარი პატარა ზომის კატებისთვის (1.2-2.8კგ)
№ 373-11
Verified on: 15 Oct 2026
Details: pack, label wording, sources, registration

Bravecto Plus 112.5 mg/5.6 mg, Spot-on

fluralaner 112.5 mg + moxidectin 5.6 mg, spot-on solution for cats 1.2-2.8 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Cat
8.6/10
Very good
vetman assessment

Bravecto Plus

112.5 mg/5.6 mg, fluralaner 112.5 mg + moxidectin 5.6 mg, spot-on solution for cats 1.2-2.8 kg
Assessed clinical scopeCat · Full labelled feline scope when flea or tick treatment and at least one additional parasite indication are required concurrently: fleas, ticks, ear mites, gastrointestinal nematodes, heartworm and lungworm prevention · On the skin
Care settingVeterinary-selected integrated feline parasite control after risk assessment and exact weighing
vetman score 8.6/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 373-11 · Verified on 15 Oct 2026

A strong long-interval integrated parasite product for cats when its fixed multi-parasite scope matches the patient; avoid using the combination when only a single target needs treatment.

Regulatory and scientific credibility9.5/10

The exact feline range is centrally authorised in the EU with current combined official product information and strong indication-specific trials; Georgian registration is shown separately per presentation.

Clinical efficacy9.0/10

Randomised field and controlled studies show high, sustained efficacy across fleas, ticks and labelled nematodes, including lungworm prevention; the fixed combination is appropriate only when ectoparasite control and another labelled parasite target are needed together.

Safety and tolerability7.0/10

Generally well tolerated, but transient skin, gastrointestinal and rare neurologic reactions are recognised; young or underweight cats, reproduction, adult heartworm assessment and P-glycoprotein inhibitor combinations require specific precautions.

Clinical practicality9.0/10

One whole weight-banded pipette gives broad long-interval coverage, but direct skin placement, prevention of grooming, indication-specific retreatment and pre-treatment parasite-risk assessment are essential.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use only when treatment against ticks or fleas and at least one other labelled parasite is indicated concurrently; this fixed combination is not justified for a single target alone.
  • Do not use in hypersensitivity; treatment is not recommended below 9 weeks or 1.2 kg, in breeding males, during pregnancy or lactation.
  • In heartworm-risk areas, assess for adult Dirofilaria infection before prevention; the product does not treat adult heartworms.
  • Review concurrent P-glycoprotein inhibitors such as ciclosporin, ketoconazole, spinosad or verapamil and use only after benefit-risk assessment.
Assessment sources
  1. EU UPD Bravecto Plus 20242024
  2. Bravecto Plus ectoparasite RCT2018
  3. Bravecto Plus nematode RCT2018
  4. Bravecto Plus lungworm RCT2024
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Fluralaner112.5 mg Moxidectin5.6 mg
Formulation Type
Spot-on
Administration route
On the skin
Manufacturer
MSD Animal Health · United States
Manufacturer (register)
Intervet Productions SA, France
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 1588, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ბრავექტო™ პლუს 112.5მგ/5.6მგ გარეგანი გამოყენების ხსნარი პატარა ზომის კატებისთვის (1.2-2.8კგ)
№ 373-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-518
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
DoseSpeciesWeightRouteFrequencySource
1 pipette
corresponding to a dose of 40-94 mg fluralaner/kg body weight and 2-4.7 mg moxidectin/kg body weight Within each weight band, the content of one whole pipette should be used. Where necessary, cats can be re-treated at 12-week intervals. In the absence of available data, treatment of kittens less than 9 weeks of age and cats less than 1.2 kg bodyweight is not recommended. use in such animals is not recommended
 Cat 1.2–2.8 kg On the skin once; if needed every 12 weeks Product label (SPC)
No dose for this species
This product is labelled only for cats; no canine dose is established.
 Dog Any weight On the skin - Product label (SPC)
250 mg/12.5 mg, Spot-on · Cat 2.8–6.25 kg Cat 2.8–6.25 kg 1 pipette (0.89 ml)
Apply the entire 0.89 ml pipette to intact skin at the base of the skull. This provides 40-94 mg/kg fluralaner and 2-4.7 mg/kg moxidectin. Use only when treatment against ticks or fleas and at least one other labelled parasite is indicated concurrently. Do not use orally or on skin lesions, and prevent grooming before the site dries. It is not recommended in kittens under 9 weeks, cats under 1.2 kg, breeding males, pregnancy or lactation. Assess cats at heartworm risk for adult infection. Review P-glycoprotein inhibitor interactions before treatment.
 · Once; indication-specific retreatment under veterinary direction		 Once; indication-specific retreatment under veterinary direction Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ბრავექტო™ პლუსი 250 მგ/12.5 მგ გარეგანი გამოყენების ხსნარი საშუალო ზომის კატებისთვის (>2.8-6.25 კგ)
№ 375-11
Verified on: 21 Oct 2026
Details: pack, label wording, sources, registration

Bravecto Plus 250 mg/12.5 mg, Spot-on

fluralaner 250 mg + moxidectin 12.5 mg, spot-on solution for cats >2.8-6.25 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Cat
8.6/10
Very good
vetman assessment

Bravecto Plus

250 mg/12.5 mg, fluralaner 250 mg + moxidectin 12.5 mg, spot-on solution for cats >2.8-6.25 kg
Assessed clinical scopeCat · Full labelled feline scope when flea or tick treatment and at least one additional parasite indication are required concurrently: fleas, ticks, ear mites, gastrointestinal nematodes, heartworm and lungworm prevention · On the skin
Care settingVeterinary-selected integrated feline parasite control after risk assessment and exact weighing
vetman score 8.6/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 375-11 · Verified on 21 Oct 2026

A strong long-interval integrated parasite product for cats when its fixed multi-parasite scope matches the patient; avoid using the combination when only a single target needs treatment.

Regulatory and scientific credibility9.5/10

The exact feline range is centrally authorised in the EU with current combined official product information and strong indication-specific trials; Georgian registration is shown separately per presentation.

Clinical efficacy9.0/10

Randomised field and controlled studies show high, sustained efficacy across fleas, ticks and labelled nematodes, including lungworm prevention; the fixed combination is appropriate only when ectoparasite control and another labelled parasite target are needed together.

Safety and tolerability7.0/10

Generally well tolerated, but transient skin, gastrointestinal and rare neurologic reactions are recognised; young or underweight cats, reproduction, adult heartworm assessment and P-glycoprotein inhibitor combinations require specific precautions.

Clinical practicality9.0/10

One whole weight-banded pipette gives broad long-interval coverage, but direct skin placement, prevention of grooming, indication-specific retreatment and pre-treatment parasite-risk assessment are essential.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use only when treatment against ticks or fleas and at least one other labelled parasite is indicated concurrently; this fixed combination is not justified for a single target alone.
  • Do not use in hypersensitivity; treatment is not recommended below 9 weeks or 1.2 kg, in breeding males, during pregnancy or lactation.
  • In heartworm-risk areas, assess for adult Dirofilaria infection before prevention; the product does not treat adult heartworms.
  • Review concurrent P-glycoprotein inhibitors such as ciclosporin, ketoconazole, spinosad or verapamil and use only after benefit-risk assessment.
Assessment sources
  1. EU UPD Bravecto Plus 20242024
  2. Bravecto Plus ectoparasite RCT2018
  3. Bravecto Plus nematode RCT2018
  4. Bravecto Plus lungworm RCT2024
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Fluralaner250 mg Moxidectin12.5 mg
Formulation Type
Spot-on
Administration route
On the skin
Manufacturer
Intervet International B.V. · Netherlands
Manufacturer (register)
Intervet Productions SA, France
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 1590, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ბრავექტო™ პლუსი 250 მგ/12.5 მგ გარეგანი გამოყენების ხსნარი საშუალო ზომის კატებისთვის (>2.8-6.25 კგ)
№ 375-11
Verified on: 21 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-518
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
DoseSpeciesWeightRouteFrequencySource
1 pipette (0.89 ml)
Apply the entire 0.89 ml pipette to intact skin at the base of the skull. This provides 40-94 mg/kg fluralaner and 2-4.7 mg/kg moxidectin. Use only when treatment against ticks or fleas and at least one other labelled parasite is indicated concurrently. Do not use orally or on skin lesions, and prevent grooming before the site dries. It is not recommended in kittens under 9 weeks, cats under 1.2 kg, breeding males, pregnancy or lactation. Assess cats at heartworm risk for adult infection. Review P-glycoprotein inhibitor interactions before treatment.
 Cat 2.8–6.25 kg On the skin Once; indication-specific retreatment under veterinary direction
EU UPD Bravecto Plus 2024
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Bravecto Plus spot-on solution for cats - combined product information
EU Union Product Database, 2024
500 mg/25 mg, Spot-on · Cat 6.25–12.5 kg Cat 6.25–12.5 kg 1 pipette
corresponding to a dose of 40-94 mg fluralaner/kg body weight and 2-4.7 mg moxidectin/kg body weight Within each weight band, the content of one whole pipette should be used. Where necessary, cats can be re-treated at 12-week intervals. use in such animals is not recommended
 · once; if needed every 12 weeks		 once; if needed every 12 weeks Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ბრავექტო™ პლუს 500მგ/25მგ გარეგანი გამოყენების ხსნარი დიდი ზომის კატებისთვის (>6.25-12.5კგ)
№ 374-11
Verified on: 15 Oct 2026
500 mg/25 mg, Spot-on · Dog Any weight Dog Any weight No dose for this species
This product is labelled only for cats; no canine dose is established.
 - Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ბრავექტო™ პლუს 500მგ/25მგ გარეგანი გამოყენების ხსნარი დიდი ზომის კატებისთვის (>6.25-12.5კგ)
№ 374-11
Verified on: 15 Oct 2026
Details: pack, label wording, sources, registration

Bravecto Plus 500 mg/25 mg, Spot-on

fluralaner 500 mg + moxidectin 25 mg, spot-on solution for cats >6.25-12.5 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Cat
8.6/10
Very good
vetman assessment

Bravecto Plus

500 mg/25 mg, fluralaner 500 mg + moxidectin 25 mg, spot-on solution for cats >6.25-12.5 kg
Assessed clinical scopeCat · Full labelled feline scope when flea or tick treatment and at least one additional parasite indication are required concurrently: fleas, ticks, ear mites, gastrointestinal nematodes, heartworm and lungworm prevention · On the skin
Care settingVeterinary-selected integrated feline parasite control after risk assessment and exact weighing
vetman score 8.6/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 374-11 · Verified on 15 Oct 2026

A strong long-interval integrated parasite product for cats when its fixed multi-parasite scope matches the patient; avoid using the combination when only a single target needs treatment.

Regulatory and scientific credibility9.5/10

The exact feline range is centrally authorised in the EU with current combined official product information and strong indication-specific trials; Georgian registration is shown separately per presentation.

Clinical efficacy9.0/10

Randomised field and controlled studies show high, sustained efficacy across fleas, ticks and labelled nematodes, including lungworm prevention; the fixed combination is appropriate only when ectoparasite control and another labelled parasite target are needed together.

Safety and tolerability7.0/10

Generally well tolerated, but transient skin, gastrointestinal and rare neurologic reactions are recognised; young or underweight cats, reproduction, adult heartworm assessment and P-glycoprotein inhibitor combinations require specific precautions.

Clinical practicality9.0/10

One whole weight-banded pipette gives broad long-interval coverage, but direct skin placement, prevention of grooming, indication-specific retreatment and pre-treatment parasite-risk assessment are essential.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use only when treatment against ticks or fleas and at least one other labelled parasite is indicated concurrently; this fixed combination is not justified for a single target alone.
  • Do not use in hypersensitivity; treatment is not recommended below 9 weeks or 1.2 kg, in breeding males, during pregnancy or lactation.
  • In heartworm-risk areas, assess for adult Dirofilaria infection before prevention; the product does not treat adult heartworms.
  • Review concurrent P-glycoprotein inhibitors such as ciclosporin, ketoconazole, spinosad or verapamil and use only after benefit-risk assessment.
Assessment sources
  1. EU UPD Bravecto Plus 20242024
  2. Bravecto Plus ectoparasite RCT2018
  3. Bravecto Plus nematode RCT2018
  4. Bravecto Plus lungworm RCT2024
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Fluralaner500 mg Moxidectin25 mg
Formulation Type
Spot-on
Administration route
On the skin
Manufacturer
MSD Animal Health · United States
Manufacturer (register)
Intervet Productions SA, France
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 1589, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ბრავექტო™ პლუს 500მგ/25მგ გარეგანი გამოყენების ხსნარი დიდი ზომის კატებისთვის (>6.25-12.5კგ)
№ 374-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-518
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
DoseSpeciesWeightRouteFrequencySource
1 pipette
corresponding to a dose of 40-94 mg fluralaner/kg body weight and 2-4.7 mg moxidectin/kg body weight Within each weight band, the content of one whole pipette should be used. Where necessary, cats can be re-treated at 12-week intervals. use in such animals is not recommended
 Cat 6.25–12.5 kg On the skin once; if needed every 12 weeks Product label (SPC)
No dose for this species
This product is labelled only for cats; no canine dose is established.
 Dog Any weight On the skin - Product label (SPC)
Active substance doses, with sources
Active substance Fluralaner
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
25–56 mg/kg Dog Maintenance By mouth every 12 weeks
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Bravecto 112.5 mg chewable tablets for very small dogs (2 - 4.5 kg) - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
Active substance Moxidectin
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
2.5–6.25 mg/kg Dog Maintenance On the skin monthly
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Advocate 400 mg + 100 mg spot-on solution for extra-large dogs (> 25-40 kg) - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
1–2 mg/kg Cat Maintenance On the skin monthly
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Advocate 40 mg + 4 mg spot-on solution for small cats (<= 4 kg) and ferrets - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025

Known Contraindications

  • Critical Fluralaner
    Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
    Sources: VMD SPC · VMD
  • Warning Fluralaner (Dog)
    Adverse events have been reported following use in breeding females. Before use in breeding female dogs, refer to Post-Approval Experience and Animal Safety sections. In some cases, birth defects (including limb deformities and cleft palate), stillbirth, and abortion have been reported after treatment of breeding females. The safety of the veterinary medicinal product in breeding, pregnant and lactating dogs has been demonstrated. Can be used in breeding, pregnant and lactating dogs.
    Sources: VMD SPC · VMD · FDA
  • Warning Fluralaner (Dog)
    In the absence of available data, the veterinary medicinal product should not be used on puppies less than 8 weeks old and /or dogs weighing less than 2 kg.
    Sources: VMD SPC · VMD
  • Caution Fluralaner (Dog)
    Fluralaner is a member of the isoxazoline class. This class has been associated with neurologic adverse reactions including tremors, ataxia, and seizures. Seizures have been reported in dogs receiving isoxazoline class drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. Use with caution in dogs with pre-existing epilepsy. Muscle tremor, Ataxia, Convulsion.
    Sources: VMD SPC · VMD · FDA
  • Caution Fluralaner (Dog)
    The minimum age for fluralaner depends on the product label. Some labels permit use from 8 weeks, whereas the US 12-week product claim applies only from 6 months of age and 2 kg body weight; 12-week efficacy has not been demonstrated in younger puppies.
    Sources: VMD SPC · VMD · FDA
  • Critical Moxidectin
    Do not use in cases of hypersensitivity to the active substances or to any of the excipients.
    Sources: VMD SPC · VMD
  • Critical Moxidectin (Dog)
    Do not use in puppies under 7 weeks of age. The safe use... has not been established in puppies and dogs less than 7 weeks of age or less than 3 lbs. body weight.
    Sources: VMD SPC · VMD · FDA
  • Critical Moxidectin (Cat)
    Do not use in kittens under 9 weeks of age. Do not use on cats less than 9 weeks of age or less than 2 lbs. body weight.
    Sources: VMD SPC · VMD · FDA
  • Warning Moxidectin
    The safety of the veterinary medicinal product has not been established during pregnancy and lactation in the target species.... The use is not recommended during pregnancy and lactation. Fertility: Do not use in breeding animals. The safety... has not been established in breeding, pregnant, or lactating
    Sources: VMD SPC · VMD · FDA
  • Warning Moxidectin
    The use is not recommended during pregnancy and lactation.
    Sources: VMD SPC · VMD · FDA
  • Warning Moxidectin (Dog)
    special care should be taken with Collie or Old English Sheep dogs and related breeds or crossbreeds... in particular, oral uptake by Collie or Old English Sheep dogs and related breeds or crossbreeds should be prevented. Dogs with this mutation may develop signs of severe avermectin toxicity if they ingest this product. The most common breeds associated with this mutation include Collies and Collie crosses.
    Sources: VMD SPC · VMD · FDA
  • Warning Moxidectin (Dog)
    Do not use in dogs classified as Class 4 for heartworm disease has not been evaluated in heartworm-positive dogs with Class 4 heartworm disease
    Sources: VMD SPC · VMD · FDA
  • Warning Moxidectin (Cat)
    use of the veterinary medicinal product on cats or ferrets which have adult heartworms may cause serious adverse effects, including death No adverse reactions were associated with the topical application... to experimentally heartworm-infected cats.
    Sources: VMD SPC · VMD · FDA
  • Warning Moxidectin (Cat)
    Do not use on sick, debilitated, or underweight cats Several otherwise healthy, thin geriatric cats experienced prolonged lethargy and sleepiness after using this drug.
    Sources: VMD SPC · VMD · FDA
  • Caution Moxidectin (Dog)
    Use with caution in sick, debilitated, or underweight animals.
    Sources: VMD SPC · VMD · FDA
  • Known Breed Sensitivities Moxidectin
    Collie, Collie (unspecified), Collie - Scottish Rough, Collie - Scottish Smooth, Sheepdog - Old English
    special care should be taken with Collie or Old English Sheep dogs and related breeds or crossbreeds... oral uptake... should be prevented.

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Show all related products (80 more) Hide additional products

Same therapeutic group 80

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 21 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗